Toxicology is the scientific study of the adverse effects of chemicals or poisons on living systems. Poisoning refers to the bodily entry of a toxic substance in amounts that cause dysfunction of body systems.

• Poisoning: Voluntary or accidental ingestion, inhalation, or absorption of a toxic substance.
• Antidote: A chemical substance that specifically stops, reverses, or counteracts the effects of a poison.

• Microorganisms: e.g., bacterial toxins in food poisoning.
• Inorganic sources: e.g., lead, mercury, copper metal poisoning.
• Organic sources: e.g., agricultural chemicals (organophosphates), paraffin, petrol.
• Drug abuse / Overdose: e.g., alcohol, opioids, or medicines in excess amounts (paracetamol, aspirin).

Optimal management depends on the specific poison taken, presenting and suspected illness, and the time that has elapsed between exposure and presentation. Rule of thumb: In a hospital setting, admit all patients with a history or signs of poisoning even if they currently appear well.

1. Supportive Care (ABCs & Vitals):
   • Airway and Breathing: Position the patient in a semi-prone (lateral recovery) position to minimize the risk of aspiration of vomitus. Maintain a patent airway and if necessary, assist in ventilation. Administer oxygen.
   • Blood Pressure (Circulation): If hypotensive, raise the foot of the bed and start IV Normal Saline (N/S). If hypertensive, manage appropriately.
   • Temperature Control: If hypothermic, cover with heavy blankets. If hyperthermic, perform tepid sponging and give antipyretics.
   • Convulsion Management: Give Diazepam 10mg rectally or 5-10mg as slow IV in adults (Max dose is 30mg). In children, give 0.5mg/kg rectally or 0.2mg/kg as IV.
2. Decontamination (Removal and Elimination):

   Decontamination must be implemented after the stabilization of vitals.

   • Gastric Emptying: Do not induce vomiting. Balance the dangers of gastric emptying against the likely toxicity of the swallowed medicine. Insert an NG tube and perform gastric lavage. It is highly useful if done within 2 hours of ingestion. Contraindicated in: comatose patients (without a protected airway), and in corrosive or petroleum product ingestion.
   • Prevention of Absorption: Administer Activated Charcoal to bind the poison in the stomach and reduce absorption. Give 50g (or 25g-50g) repeated every 4 hours if necessary. Grind the tablets into fine powder then mix with 100mls of water. In children, give 0.5-1g/kg. This is effective within 2 hours of ingestion. Contraindicated in: intestinal obstruction, corrosive/petroleum products, toxins poorly absorbed by charcoal (e.g., metals, alcohol), and depressed mental status (late presentation without an airway).
3. Specific Antidote Therapy (Discussed in sections below).
4. Counseling: Counsel patients and families on poisoning prevention and mental health support.

• Opioids: All natural, synthetic, and semisynthetic agents with morphine-like actions.
• Opiates: Naturally occurring opioids derived from the poppy plant.
• Opium: (Greek for juice) in reference to poppy juice from the opium poppy (Papaver sp.).
  • Morphine (the prototype) was isolated by Sertürner in 1803 and named after Morpheus (the Greek god of dreams). It produces profound analgesia, sedation, and euphoria.
• Endorphins: Endogenous opioid peptides (endomorphins, dynorphins, enkephalins) produced naturally in the body.
• Narcotic: Broadly refers to any agent that induces sleep (nonspecific).

• The global prevalence of opiate use (heroin, morphine, and opium) is roughly 0.4% of the population aged 15-64 years.
• The global number of opiate users increased from 17.7 million in 2015 to 19.4 million in 2016.
• 70,000 to 100,000 people die from opioid overdose each year globally.
• In Africa, massive seizures of counterfeit tramadol occur regularly (e.g., 40 million pills seized in Cotonou, Benin; heavy illicit trade in Nigeria, Ghana, Togo, Niger, Sierra Leone, Cameroon).
• In the US (CDC 2010), enough opioid analgesics were sold to medicate every American adult with a typical dose of 5 mg of hydrocodone every 4 hours for 1 month.

• Morphine: M, Miss Emma, Monkey, China Girl, Murder-8.
• Heroine: The Dragon, Snowball, Tar, White, White Nurse.
• Tramadol: Chill pill, Tramal Lite, Trammies. (The Super Tramadol-X 200 brand is known in Cameroon as 'tomatoes').

Classification by Source	Classification by Potency
Natural opioids: Codeine, Morphine Semi-synthetic: Hydrocodone, Heroin (diacetylmorphine) Synthetic: Fentanyl, Tramadol, Pethidine (meperidine)	Strong Agonists: Morphine, Oxymorphone, Heroin, Methadone, Fentanyl, Pethidine. Mild to Moderate Agonists: Oxycodone, Codeine, Dihydrocodeine, Tramadol.

• Absorption: Well absorbed enterally or parenterally. Routes include transdermal patches, rectal suppositories, buccal transmucosal (lozenges), and oral (subject to high 1st pass effect). Serum therapeutic doses are reached 1 to 2 hrs after oral ingestion. Heroin peaks extremely fast: IV (1 min), inhalation (3-5 min), SC (10 min).
• Distribution: High volume of distribution; easily crosses the Blood-Brain Barrier (BBB). Predilection for highly perfused tissues (brain, lungs, liver, kidneys, spleen). Adipose tissues are poorly perfused but serve as dangerous reservoirs for lipophilic opioids (like fentanyl).
• Metabolism: All opioids undergo hepatic metabolism via Cytochrome P450 enzymes.
  • Morphine undergoes glucuronidation into morphine-3-glucuronide (M3G - neuroexcitatory properties) and morphine-6-glucuronide (M6G - 4 to 6 times more potent analgesia).
  • Heroin is rapidly hydrolyzed to morphine.
  • Pethidine and Fentanyl undergo hepatic oxidation.
  • CYP2D6 Polymorphism: Codeine and Tramadol are metabolized by CYP2D6 into active forms (Morphine & O-desmethyltramadol respectively). Oxycodone is also metabolized by CYP2D6 (into less active metabolites). Fentanyl is metabolized by CYP3A5 into inert metabolites. Genetic polymorphism causes massive interindividual variability and dangerous drug interactions.
• Excretion: Predominantly renal elimination. Renal impairment heavily increases the risk of toxicity. Dialysis cannot clear opioids effectively.

• Receptors: 3 main types: mu (μ), kappa (κ), and delta (δ). Present in the CNS (dorsal horn of spinal cord, areas of nociception, respiratory center, and reward/euphoria centers) and Systemically (sensory nerves, GIT, CVS endothelium, immune cells).
• Mechanism: They close voltage-gated Ca2+ channels on the presynaptic nerve to drastically reduce neurotransmitter release (Glutamate, Acetylcholine, Norepinephrine, Serotonin, and Substance P). They also hyperpolarize postsynaptic neurons by opening K+ channels. This activates descending inhibitory pathways that block pain transmission.

• Analgesia (Myocardial Infarction, renal colic, cancer patients, obstetrics).
• Antidiarrheal effects (e.g., Loperamide, Lomotil).
• Antitussives (e.g., Codeine in cough mixtures).
• Anti-Shivering (e.g., Pethidine).
• Anaesthesia (Pre-medicant due to sedative, anxiolytic, and analgesic effects; as an adjunct intra-operatively; or for regional epidural/subarachnoid block).

• People at risk: Opioid-dependent individuals, especially those with reduced tolerance (e.g., recently released from incarceration or rehab); people on prescribed opioids; users combining opioids with other sedatives (alcohol, benzos); people with lung, liver, or renal impairment; household members (accidental ingestion by children).
• Source of history: Witnesses, friends, families, health care workers, police, emergency service workers, outreach/peer workers. Note the time of ingestion, quantity, and co-ingestants.
• Clues: Pill bottles, drug paraphernalia (spoons, lighters, syringes, tourniquets), or eyewitness accounts.

A voluntary or accidental overdose leads to life-threatening physiological changes. The hallmark is the Opioid Toxidrome.

Other Systemic Features:

• Physical/Dermatological: Needle tracks are often evident (Skin-popping/SC injections, and Mainlining/IV). Powdery substances around the nose. Pruritus (itching), flushed skin, and urticaria due to histamine release.
• Respiratory: Acute Lung Injury (ALI), presenting with pink frothy sputum, severe dyspnea, bronchospasm, and muscular rigidity (wooden chest).
• Cardiovascular: Hypotension (Orthostatic), bradycardia, and arrhythmias. Exception: Pethidine, cocaine co-ingestion, or severe cerebral hypoxia can cause paradoxical tachycardia and hypertension.
• Gastrointestinal: Nausea, vomiting, severe constipation, and in severe cases, paralytic ileus (absent bowel sounds).
• Renal: Urinary retention due to urethral sphincter spasm and decreased detrusor tone. Heroin nephropathy.
• Special CNS Features:
  • Seizures: Specifically seen with Pethidine, Propoxyphene, and Tramadol overdoses.
  • Parkinsonian symptoms: Bradykinesia, resting tremors, rigidity, and postural instability. (Often seen with Pethidine produced in street labs containing MPTP metabolites, causing focal lesions in the Substantia nigra).
  • Heroin Associated Spongiform Leukoencephalopathy (HASL): Causes psychomotor retardation, dysarthria, ataxia, tremor.
  • Serotonin Syndrome: Caused by ingesting opioids with serotonergic properties (Pethidine, Tramadol, Fentanyl, Oxycodone, Methadone) alongside MAOIs, SSRIs, or TCAs. Presents with altered mental status, autonomic instability (hyperthermia, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, clonus, rigidity).

• Biochemistries: RBS (Random Blood Sugar to rule out hypoglycemia), BUE (Urea), and Creatinine (Renal function).
• Continuous SPO2 monitoring and Arterial Blood Gases (ABGs) to check for hypoxia/hypercapnia.
• 12-lead ECG: Crucial for detecting QRS widening, QT prolongation, or Torsades de pointes (especially dangerous with propoxyphene or methadone).
• Chest X-ray (CXR): To detect hypoxemia complications, pulmonary edema, and coarse crackles (rales).
• Abdominal X-ray: Mandatory to rule out "Body packers/mules" (drug smuggling via swallowed packets).
• Urine Toxicology Screen: Remains positive for days after last use.
• Serum acetaminophen and salicylate levels (frequently co-ingested).

• Benzodiazepine and Barbiturate toxicity
• Hypoglycemia (always check blood sugar!)
• Gamma-hydroxybutyrate (GHB) toxicity ("liquid ecstasy")
• Clonidine toxicity
• Alcohol toxicity
• Cannabinoid poisoning
• Meningitis

The primary aim is restoring respiration, not necessarily restoring full consciousness.

• Airway & Breathing: Provide Supplemental Oxygen via Bag-Valve-Mask (BVM). If the airway is unprotected or respiratory failure is profound, proceed to Endotracheal intubation. Continuous cardio-respiratory monitoring.
• Circulation & Fluids: Correction of dehydration and/or electrolyte imbalance using IV Ringer's Lactate (RL) or Normal Saline (NS).
• Metabolic: Immediate correction of Hypoglycemia with IV Dextrose.
• Seizure Control: Abortion of any active seizures using IV Diazepam.
• GIT Decontamination: If the patient is a body packer, has taken a multi-drug ingestion, or an opioid combination product, use whole-bowel irrigation and activated charcoal (only if the airway is secure).

Indicated in cases of significant CNS and respiratory depression.

• Naloxone (Narcan): A pure competitive antagonist.
  • Onset: 1-2 minutes. Maximal effect: 5-10 minutes. Duration of action: 1 to 2 hours (often shorter than the opioid, requiring repeat dosing).
  • Adult Dose: 0.4 to 2 mg IV, IM, or SC. Repeat every 2-3 minutes if not improving, up to a maximum of 10 mg. (Also available as an Intranasal spray at 0.4mg/spray).
  • Pediatric Dose: 0.1 mg/kg IV in children < 5 yrs; OR 0.1-2mg/dose in children > 5 yrs.
  • Chronic Users / Dependent Patients: Give tiny aliquots of 0.04 to 0.2 mg IV and slowly titrate up. This avoids precipitating an acute, explosive withdrawal syndrome.
  • Contraindication: Naloxone must be used with extreme caution or is relatively contraindicated in opioid-induced respiratory depression in chronic opioid use, such as in palliative care for terminal cancer patients, as it will cause a massive, intractable pain crisis.
  • Diagnostic check: Reconsider the diagnosis if the patient completely fails to respond after 10 mg of Naloxone.
• Nalmefene: A longer-acting alternative antagonist.

• Asymptomatic adults: Must be observed for at least 4 hours post-ingestion or post-Naloxone.
• Asymptomatic children: Must be observed for at least 24 hours.
• Adults with respiratory depression: Admitted to ICU/HDU for 12-24 hours.
• Length of detention: Highly dependent on the half-life of the specific opioid. (e.g., Diphenoxylate-atropine / Lomotil has a very long T1/2 and requires prolonged monitoring).
• Body Packers: Discharged only after definitively passing out all packets (confirmed by clear imaging).
• Psychiatric Follow-up: Mandatory psychiatric evaluation or drug abuse counseling prior to discharge. Discharge only to a stable social setting.

• Acute Lung Injury (ALI) / Non-cardiogenic pulmonary edema
• Cellulitis and Osteomyelitis (from dirty needles)
• Horner Syndrome
• Infective Endocarditis
• Heroin Associated Spongiform Leukoencephalopathy (HASL)
• Heroin Nephropathy
• Parkinsonian disorder
• Severe Withdrawal syndrome

Benzodiazepines (e.g., Diazepam, Midazolam) are used for anxiety and as sedatives. Overdose can be intentional or accidental.

• Clinical Presentations: Confusion, severe drowsiness, hypotension, unresponsiveness/coma, respiratory depression (especially when mixed with alcohol or opioids), nystagmus, slurred speech, and body weakness/hypotonia.
• Management:
  • Supportive care (Airway, Breathing).
  • Administer activated charcoal if presentation is recent (within 1-2 hours) and airway is protected.
  • Specific Antidote: Flumazenil. Give 0.2 mg IV over 30 seconds. Repeat if necessary. (Use with caution in chronic users as it can precipitate life-threatening seizures).

• Management: Obtain a baseline prothrombin time and international normalized ratio (PT/INR) and arrange for repeat measurements.
• Specific Antidote: If the INR is dangerously elevated or there is active bleeding, reverse the effects with Vitamin K1 (Phytomenadione). Give 10mg orally or by slow IV infusion.
• For urgent, immediate reversal of life-threatening bleeding, administer Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrate (PCC) (also known as factor IX complex).

Accidental or intentional consumption. The toxic dose is >150mg/kg or >7.5g in adults.

• Clinical Features (Stages):
  • First 24 hours: The individual may be asymptomatic or present with non-specific nausea, vomiting, malaise, and abdominal pain.
  • 24-72 hours: Progressive signs of severe hepatotoxicity appear (right upper quadrant pain, enlarged tender liver, and drastically raised Liver Function Tests/LFTs).
  • After 72 hours: Either recovery after 5-7 days or progression to fulminant hepatic failure, coagulopathy, encephalopathy, and death.
• Management:
  • If ingestion occurred less than 2 hours ago, perform gastric lavage and give repeated doses of activated charcoal (25-50g every 4 hours).
  • Specific Antidote: N-acetylcysteine (NAC). Best if started within 8 hours of ingestion. It reduces toxicity by providing cysteine for glutathione synthesis (a powerful antioxidant). Glutathione reacts with the toxic metabolite (NAPQI) so it can be safely excreted without destroying liver cells.
  • NAC IV Protocol: 150mg/kg (max 15g) in 200mls D5W over 60 minutes; followed by 50mg/kg (max 5g) in 500ml D5W over 4 hours; followed by 100mg/kg (max 10g) in 1000ml D5W over 16 hours.

Overdose occurs with consumption of > 10g in adults and > 3g in children.

• Clinical Features: Mild to moderate toxicity features hyperventilation (causing primary respiratory alkalosis), nausea, vomiting, vasodilation, and tinnitus (ringing in ears). Severe toxicity leads to hyperpyrexia, convulsions, altered mental status, and a profound metabolic acidosis.
• Management: Activated charcoal. Correct fluid and electrolyte imbalances. Alkalinization of urine using IV Sodium Bicarbonate enhances the excretion of salicylates. Hemodialysis is required for severe, life-threatening toxicity.

Methanol is an industrial solvent and an ingredient in methylated spirits. It is heavily associated with home-distilled crude alcohol. Ingestion of >1g/kg is lethal. It is transformed by alcohol dehydrogenase into toxic formic acid, causing severe anion-gap metabolic acidosis.

• Clinical Features: Initially presents with headache, dizziness, nausea, vomiting, and visual disturbances ("snowstorm" vision). Later causes CNS depression, respiratory failure, coma, and irreversible retinal optical nerve damage (blindness).
• Management: Gastric lavage if within 1 hour. Charcoal is not effective. Give IV fluids to manage shock. Hemodialysis is highly effective.
• Specific Antidote: Fomepizole or Ethanol (which competitively inhibits alcohol dehydrogenase, stopping the conversion of methanol into toxic acid).

• Presents with severe hemorrhagic gastroenteritis, shock, and hepatotoxicity.
• Specific Antidote: Deferoxamine. Give a continuous infusion of 5mg/kg/hr to 15mg/kg/hr in N/S or D5W until metabolic acidosis clears or symptoms improve. Avoid in cases of severe renal failure.

Includes paraffin, petrol, paint thinners, and organic solvents.

• Clinical Features: Smell of hydrocarbons on breath, burning sensation in the mouth/throat, pallor, severe dyspnea, tachypnea, coughing, lethargy, vomiting, and bloody stool.
• Management: Remove contaminated clothes and wash skin with soap and water. Administer oxygen if hypoxic. Treatment is strictly supportive.
• CRITICAL WARNING: Strictly avoid gastric lavage, use of enemas, or induction of vomiting. Do not give charcoal. These hydrocarbons have low viscosity and high volatility; attempting to empty the stomach leads to a massive risk of aspiration, resulting in fatal chemical pneumonitis.

Toxin / Poison	Specific Antidote
Opioids / Narcotics (Morphine, Heroin, Tramadol)	Naloxone (Narcan) or Nalmefene
Benzodiazepines (Diazepam, Midazolam)	Flumazenil
Paracetamol (Acetaminophen)	N-acetylcysteine (NAC)
Warfarin	Vitamin K1 (Phytomenadione) / FFP
Methanol / Ethylene Glycol	Fomepizole or Ethanol
Iron	Deferoxamine
Organophosphates (Insecticides)	Atropine and Pralidoxime (2-PAM)
Carbon Monoxide	100% Oxygen (Hyperbaric Oxygen if severe)

No.	Nursing Diagnosis	Interventions & Rationale
1	Ineffective Breathing Pattern related to CNS and respiratory center depression secondary to drug overdose (e.g., opioids, benzodiazepines).	Continuously monitor RR, depth, and SpO2: Detects early signs of respiratory failure requiring intervention. Administer 100% Oxygen and assist ventilation with BVM: Maintains oxygenation to prevent hypoxic brain injury if spontaneous breathing is inadequate. Administer specific antidotes (e.g., Naloxone) as prescribed: Competitively binds receptors to rapidly reverse central respiratory depression.
2	Risk for Aspiration related to depressed level of consciousness, absent gag reflex, or forceful emesis post-poisoning.	Position patient in the lateral recovery position: Prevents the tongue from occluding the airway and utilizes gravity to drain vomitus out of the mouth. Keep functional suction equipment at the bedside: Ensures immediate clearing of the airway if the patient vomits. Strictly avoid inducing vomiting for petroleum distillates: Aspiration of these chemicals causes fatal lipoid/chemical pneumonitis.
3	Decreased Cardiac Output related to myocardial depression, hypovolemia, or toxin-induced arrhythmias (e.g., methadone prolonging QT).	Monitor continuous 12-lead ECG and vital signs: Early detection of fatal arrhythmias like Torsades de pointes. Administer IV isotonic crystalloids (Normal Saline/RL): Expands intravascular volume to correct toxin-induced hypotension. Elevate the foot of the bed: Promotes venous return to the heart to improve systemic perfusion.
4	Deficient Knowledge / Ineffective Coping related to psychological dependence, lack of problem-solving skills, and risk of relapse.	Establish a non-judgmental, therapeutic relationship: Builds trust, encouraging the patient to express feelings about drug use honestly. Educate the patient and family on safe storage of medicines and household chemicals: Prevents accidental pediatric ingestion. Refer to psychiatric services, substance abuse counseling, and support groups (e.g., NA): Provides long-term community support for sustained rehabilitation and social reintegration.

• Rosen Emergency Medicine 8th Edition, Opioids.
• Katzung Basic & Clinical Pharmacology 12th Edition.
• World Health Organization (WHO) Community Management of Opioid Overdose (2014) & Critical Review Report: Tramadol (2018).
• Nelson Textbook of Paediatrics 20th Edition (2015).
• Medscape Clinical Guidelines: Opioid Toxicity and General Poisoning Management.

ALCOHOLISM

Alcoholism is a chronic condition characterized by excessive and prolonged alcohol consumption, leading to severe physical, social, and mental adverse effects, and an increased physical and social dependency on alcohol.

Key Terms and Definitions:

• Drug (Substance): Any chemical agent that, once ingested, can cause physiological and psychological changes.
• Alcoholic: An individual who excessively consumes alcohol, leading to mental, social, physical, and psychological problems.
• Substance Intoxication: A reversible, substance-specific syndrome that develops due to recent ingestion or exposure to a drug.
• Alcohol Intoxication: A temporary mental disturbance following heavy drinking, where blood alcohol levels are high enough to affect activity, mood, and consciousness.
• Tolerance: The need for increasing amounts of a drug to achieve the same effect previously obtained with a lower dose.
• Dependency: A compulsion to continuously take a drug to experience its effects and avoid the discomfort of its absence. This can be physical (bodily response) or psychological.
• Addiction: A psychological and physical inability to stop consuming a drug despite it causing psychological and physical harm, characterized by continued use despite negative consequences.
• Misuse: Incorrect, excessive, or non-therapeutic use of mind-altering substances.

Causes of Alcohol Abuse:

1. Availability: Easy access to alcohol and societal acceptance of drinking (e.g., at social gatherings).
2. Genetic Factors: A family history of excessive drinking suggests a genetic predisposition.
3. Poor Coping Strategies: Individuals struggling with stress may resort to alcohol as a coping mechanism.
4. Psychiatric Disorders: Co-occurring conditions like depressive, anxiety, or phobic disorders can lead to alcohol abuse.
5. Social Disorders: Factors such as isolation, unemployment, loss, bereavement, or injustice.
6. High-Risk Groups: Includes those with chronic physical illnesses, business executives, traveling salespersons, industrial workers, hostel students, and military personnel.
7. Age: Most common between late adolescence and early adulthood.

Process of Alcoholism:

The development of alcoholism often follows a progression:

1. Experimental Stage: Initial consumption due to peer pressure, influences, or curiosity.
2. Recreational Stage: Enjoyment of alcohol during weekends or holidays. In small amounts, it may relieve tension, relax the mind, or promote well-being.
3. Compulsive Stage: Regular, heavy drinking to achieve pleasure or avoid withdrawal discomfort.

Stages of Alcoholism:

The text outlines distinct stages:

• Early Stage:
  • Increased Tolerance: Needing more alcohol for the desired effect.
  • Blackouts: Inability to recall events while intoxicated.
  • Preoccupation: Constant thoughts about drinking.
• Middle Stage:
  • Loss of Control: Inability to limit amount or frequency of drinking.
  • Cycles of Abstinence: Brief periods without alcohol, followed by obsessive drinking.
• Chronic Stage:
  • Low Tolerance: Getting drunk on small amounts.
  • Prioritizing Alcohol: Alcohol takes precedence over family or job; willingness to lie, beg, borrow, or steal for supply.

Types of Drinkers:

1. Mild Drinkers: Rarely and occasionally consume small amounts, or large amounts infrequently, with minimal problems.
2. Moderate Drinkers: Consume in moderation, without excess, generally avoiding significant health issues.
3. Problem Drinkers: Consume large amounts daily, often with high concentrations, leading to impaired health, mental distress, family disruption, loss of reputation, and poor performance.

Effects and Complications of Alcohol:

A. Physical or Medical Effects:

• Hepatitis and Liver Cirrhosis
• Pancreatitis
• Peptic Ulcers and Gastritis
• Cardiomyopathies and Heart Failure
• Epileptic-like Fits (RUM Fits - alcohol withdrawal seizures)
• Tuberculosis
• Weight Loss
• Alcoholic Dementia
• Anemia
• Malnutrition
• Lowered Immunity

B. Psychiatric Effects:

• Depression
• Pathological Intoxication: Maladaptive behavioral effects (e.g., fighting, impaired judgment, slurred speech, mood changes, irritability, impaired attention).
• Delirium Tremens (DTs): Severe withdrawal syndrome with confusion, hallucinations, and autonomic instability.
• Alcoholic Hallucinosis: Vivid hallucinations shortly after reducing or stopping alcohol.
• Alcoholic Psychosis: Psychotic disorder resembling paranoid schizophrenia (delusions, hallucinations, primary mental function impairment) after prolonged, heavy drinking.
• Alcohol Amnestic Disorder: Impairment in short and long-term memory, disorientation, and confabulation.
• Alcoholic Dementia: Chronic organic mental disorder resulting in irreversible memory and orientation impairment.
• Suicide
• Anxiety
• Paranoia: Persecutory ideation and self-hate.
• Morbid or Pathological Jealousy: Irrational jealousy, often directed at a partner.
• Hallucinations
• Wernicke’s Encephalopathy: Acute deficiency of Vitamin B1 (Thiamine) in alcoholics, causing neurological symptoms.
• Korsakoff Syndrome: Gradual depletion of thiamine, leading to severe memory problems and confabulation.

C. Social Problems:

• Decreased work performance and productivity (due to chronic absenteeism).
• Family problems (e.g., divorce).
• Increased accidents (e.g., drunk driving).
• Legal effects (e.g., rape, theft).
• Violence and aggression.

Diagnosis of Alcoholism:

1. History Taking: Comprehensive assessment of upbringing, family background, duration of abuse, etc.
2. Clinical Presentation: Observable signs like curly hair, swollen cheeks, red lips, poor hygiene, etc.
3. CAGE Questionnaire: A screening tool:
   • C - Have you ever felt you should Cut down on your drinking?
   • A - Have people Annoyed you by criticizing your drinking?
   • G - Have you ever felt Guilty about your drinking?
   • E - Have you ever had an Eye-opener first thing in the morning to get rid of a hangover or calm your nerves?
   • Interpretation: Two or more "yes" answers are highly suggestive of alcoholism.

Concentration of Alcohol in Blood and Effects:

• 80-150 mg/100ml: Intoxication
• 150-300 mg/100ml: Fatal (high risk of death)
• 300-500 mg/100ml: Very Fatal (extremely high risk of death)
• 500 mg/100ml and above: Leads to death
• Note: These effects can vary based on individual tolerance.

Management of Alcoholism:

A. Aims of Management:

• Detoxify the patient (in acute stages).
• Improve social relationships and support.
• Develop confidence and ability to change.
• Identify reasons for change.
• Develop alternative activities.
• Learn to prevent relapse.

B. Admission:

• Hospitalization is crucial to prevent alcohol access; often 6-8 weeks initially.
• Admit to a psychiatric hospital in a well-lit, quiet, open room to reduce fear and illusions.
• Establish a good nurse-patient relationship.
• Remove potentially harmful objects to prevent self-harm.
• Keep the bed dry, clean, and warm due to possible incontinence.
• Monitor vital signs every 15 minutes initially, including physical and mental behavior.
• Investigations: Urine for sugar, blood for hemoglobin level and sugars, blood alcohol level.

C. Medication:

• Minor Tranquilizers (Anxiolytics): Librium (chlordiazepoxide) and Diazepam (Valium) parenterally for anxiety, insomnia, agitation, and tremors (these are benzodiazepines, crucial for withdrawal management).
• Anticonvulsants: For withdrawal seizures ("rum fits").
• Vitamins: Plenty of B vitamins (especially Thiamine B1, B6, B12 – 100-300mg BID for 7 days), B complex, and Vitamin C.
• Antacids: To relieve gastritis.
• Fluid & Electrolyte Correction: Intravenous infusions, fluid balance chart.
• Disulfiram (Antabuse): Administered under close supervision. It causes severe adverse reactions (nausea, vomiting, headache, palpitations, blurred vision, hypotension, dyspnea) if alcohol is consumed. Initial dose 1g, tapering down to 0.1g for maintenance (up to a year).
• Aversion Therapy (Apomorphine): Injectable emetic; causes vomiting when alcohol is smelled. The text notes this is discouraged.
• Yeast Tablets: Twice daily to induce appetite.
• Stemetil (Prochlorperazine) / Avomine (Promethazine): 5-10mg to control vomiting.
• Sedation: May be required.
• Avoid Barbiturates: Alcoholics can easily become addicted to them.

D. General Nursing Care:

• Treat Associated Conditions: Address malnutrition, vitamin deficiencies, hallucinations, delirium, gastritis, or liver diseases.
• Nutrition: Small, frequent, nutritious, and appetizing meals.
• Hygiene: Oral care, general body, and bed hygiene.
• Nurse-Patient Relationship: Acceptance by the nurse is essential to encourage socialization and participation, reducing inferiority and low self-esteem.
• Psychiatric Social Workers: Involvement in addressing social problems.
• Religious Commitment: Encouraged.
• Familial Therapy: Encouraged to help the patient stay sober.
• Social Circle Change: Encourage changing friends and associates to remove triggers.
• Alcoholics Anonymous (AA): Prepare the patient for AA, a self-help group where ex-addicts provide mutual support and guidance for sobriety.
• Discharge Planning: Plan for the patient's discharge and resettlement into the community.

Therapeutic Modalities for SUDs

Therapeutic modalities form the backbone of behavioral treatment for Substance Use Disorders (SUDs). They address the psychological, social, and behavioral aspects of addiction, helping individuals develop coping strategies, improve interpersonal relationships, and maintain abstinence.

I. Individual Therapies

Individual therapy provides a private and confidential setting for patients to explore their substance use, underlying issues, and recovery goals with a trained therapist.

A. Cognitive Behavioral Therapy (CBT):

• Core Principle: Based on the idea that thoughts, feelings, and behaviors are interconnected. CBT helps patients identify and change problematic thinking patterns and behaviors that contribute to substance use.
• Techniques:
  • Identifying Triggers: Recognizing situations, thoughts, or feelings that lead to craving and substance use.
  • Coping Skills Training: Developing healthy ways to manage stress, cravings, and high-risk situations (e.g., relaxation techniques, distraction, problem-solving).
  • Relapse Prevention: Learning to anticipate and cope with potential setbacks, developing a plan for managing a "slip."
  • Cognitive Restructuring: Challenging and changing irrational or unhelpful thoughts (e.g., "I can't cope without alcohol").
• Role in SUDs: Highly effective for many SUDs, helping patients develop self-control and build skills for long-term recovery.

B. Dialectical Behavior Therapy (DBT):

• Core Principle: Developed for individuals with severe emotion dysregulation (originally for Borderline Personality Disorder), but highly effective for SUDs, especially when co-occurring with trauma or personality disorders. Emphasizes balancing acceptance and change.
• Skills Modules:
  • Mindfulness: Learning to be present and aware without judgment.
  • Distress Tolerance: Developing strategies to cope with intense emotions and crises without resorting to substance use or other maladaptive behaviors.
  • Emotion Regulation: Learning to identify, understand, and manage intense emotions.
  • Interpersonal Effectiveness: Improving communication skills and building healthier relationships.
• Role in SUDs: Helps patients manage intense cravings, cope with emotional triggers, and develop healthier interpersonal boundaries.

C. Motivational Interviewing (MI):

• Core Principle: A person-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence.
• Key Elements (OARS):
  • Open-ended questions: Encourage detailed responses.
  • Affirmations: Recognize patient strengths and efforts.
  • Reflective listening: Show understanding and empathy.
  • Summaries: Consolidate understanding and highlight key points.
• Role in SUDs: Often used as an initial intervention to help patients move from precontemplation/contemplation to preparation/action stages of change, increasing readiness for treatment. Nurses frequently use MI techniques.

D. Psychodynamic Therapy:

• Core Principle: Explores unconscious conflicts, past experiences (especially childhood trauma), and relationship patterns that may contribute to substance use.
• Role in SUDs: May be useful for individuals whose substance use is deeply rooted in unresolved psychological issues, often as a long-term approach.

II. Group Therapies

Group therapy provides a supportive environment where individuals can share experiences, receive feedback, and learn from peers in recovery.

A. Psychoeducational Groups:

• Focus: Provide information about SUDs, relapse prevention, coping skills, and healthy lifestyle choices.
• Role in SUDs: Informative and foundational for understanding the disease and recovery process.

B. Process-Oriented Groups:

• Focus: Explore interpersonal dynamics, emotions, and behaviors within the group setting. Members provide support and challenge each other.
• Role in SUDs: Helps individuals develop social skills, address isolation, and practice new behaviors in a safe environment.

C. Relapse Prevention Groups:

• Focus: Utilize CBT principles to identify high-risk situations, develop coping strategies, and review relapse warning signs.
• Role in SUDs: Critical for maintaining long-term abstinence by equipping patients with proactive strategies.

III. 12-Step Programs

(e.g., Alcoholics Anonymous (AA), Narcotics Anonymous (NA))

• Core Principle: A mutual-help, peer-led program based on spiritual principles (though not necessarily religious). Emphasizes abstinence, working through the 12 steps, making amends, and service to others.

STEPS OF ALCOHOLICS ANONYMOUS:

1. We admitted we were powerless over alcohol – that our lives had become unmanageable. AA firmly believes that individuals cannot overcome alcoholism on their own. They are unable to exercise willpower or personal strength that could prevent them from drinking
2. Came to believe that a Power greater than ourselves could restore us to sanity. Alcoholics Anonymous is based on the belief in a higher power. For some, this higher power may be God; for others, it may be a belief in the universe itself. The point is that recovery begins, in part, by looking to an entity greater than yourself.
3. Made a decision to turn our will and our lives over to the care of God as we understood Him.
4. Made a searching and fearless moral inventory of ourselves. During this step, many participants make a list of poor decisions or character flaws. They outline hurt they caused to others, as well as feelings, like fear and guilt, that motivated some of their past actions. Once the individual has acknowledged these issues, the issues are less likely to serve as triggers to future alcohol abuse.
5. Admitted to God, to ourselves and to another human being the exact nature of our wrongs. As AA members work this step, they sit down with someone – often their sponsor – and confess everything they identified in Step 4. This step requires the recovering individual to put aside their ego and pride to acknowledge shameful past behavior. The step is also empowering, as the alcoholic no longer has to hide behind guilt and lies.
6. Were entirely ready to have God remove all these defects of character. In this step, the recovering alcoholic acknowledges that he or she is ready to have a higher power – again, whatever that may be – take away the moral shortcomings identified in
7. Humbly asked Him to remove our shortcomings. This step requires the person to focus on the positive aspects of his or her character – humility, kindness, compassion and a desire for change – as well as step away from the negative defects that have been identified.
8. Made a list of all persons we had harmed, and became willing to make amends to them all. During this step, recovering alcoholics write down a list of all the people they have hurt. Often, this list includes people they hurt during their active alcoholism; however, it may go back further to include anyone they have hurt throughout their entire lives
9. Made direct amends to such people wherever possible, except when to do so would injure them or others. Paired with Step 8, Step 9 gives recovering alcoholics the opportunity to make things right with those they have hurt. One’s sponsor can be a big source of help during this process, helping the recovering alcoholic to determine the best way to go about making amends.
10. Continued to take personal inventory and when we were wrong promptly admitted it. Linked to Step 4, this step involves a commitment to continue to keep an eye out for any defects of character. It also involves a commitment to readily admit when one is wrong, reinforcing humility and honesty.
11. Sought through prayer and meditation to improve our conscious contact with God as we understood Him, praying only for knowledge of His will for us and the power to carry that out. Step 11 commits the recovering alcoholic to continued spiritual progress. For some, this may mean reading scripture every morning. For others, it may mean a daily meditation practice. Alcoholics Anonymous doesn’t have stringent rules on what form spiritual growth takes. It simply involves a commitment to take time to reassess one’s spiritual and mental state.
12. Having had a spiritual awakening as the result of these steps, we tried to carry this message to alcoholics and to practice these principles in all our affairs practice these principles in all our affairs. The final step involves helping others and serves as motivation for many to become sponsors themselves. By going through the 12 steps, individuals have a major internal shift and part of that shift is a desire to help others.

IV. Family Therapy

• Core Principle: Recognizes that SUDs affect the entire family system. Focuses on improving family communication, establishing healthy boundaries, and addressing enabling or dysfunctional patterns.
• Approaches:
  • Family Behavioral Therapy (FBT): Focuses on teaching family members communication skills, problem-solving, and contingency management to support the patient's recovery.
  • Multisystemic Therapy (MST): Intensive, family- and community-based treatment for adolescents with serious substance use and other behavioral problems.
• Role in SUDs: Essential for healing family dynamics, creating a supportive home environment, and preventing relapse. It also provides support and education for family members, who often suffer secondary effects of the SUD.

V. Other Emerging Therapies

• Mindfulness-Based Relapse Prevention (MBRP): Integrates mindfulness practices with CBT for relapse prevention.
• Contingency Management (CM): Uses positive reinforcement (e.g., vouchers, prizes) to reward abstinence and treatment adherence. Highly effective, especially for stimulant use, but can be resource-intensive.

VI. Nursing Role in Therapeutic Modalities

• Referral: Identify appropriate therapeutic modalities based on patient needs and preferences, and facilitate referrals.
• Support: Encourage participation in therapy and support groups.
• Integration: Reinforce therapeutic concepts (e.g., coping skills, trigger identification) in daily interactions with patients.
• Psychoeducation: Provide basic information about different therapy types and what to expect.
• Advocacy: Advocate for access to these vital services.

Drug abuse or Substance abuse refers to the use of certain chemicals for the purpose of creating pleasurable effects on the brain, rather than for their intended therapeutic medical purposes. The problem has been increasing at alarming rates globally, especially among young adults.

• Narcotic Abuse (Opioid Use Disorder): The use of narcotic drugs (opioids) to seek feelings of well-being, euphoria, or numbness, other than for pain killing. It is a complex set of behaviors typically associated with misuse, developing over time with higher drug dosages.
• Drug Dependence: A state resulting from the interactions of a person and a drug in which the person has a compulsion to continue taking the drug to experience pleasurable psychological effects and sometimes to avoid severe discomfort due to withdrawal. It is divided into:
  • Physical dependence: The body adapts to the drug, and when a person abruptly stops using narcotics, they develop physiological withdrawal symptoms.
  • Psychological dependence: Using the drug for personal satisfaction and craving it, even if the risks and harms are known to the user.
• Drug Tolerance: A physiological state where more of the drug is needed to produce the same original response. This usually happens with chronic use of drugs causing dependence, pushing the user to take dangerously high doses.

Addiction is a biopsychosocial disorder. The reasons for narcotic abuse and dependence include:

• Curiosity and Experimentation: Wanting to know the taste/effect of the drug and wanting to belong or be accepted in certain peer groups (Peer Pressure).
• Escapism and Stress: Intermittent use of drugs for social or emotional reasons (e.g., depression, anxiety, PTSD, break-ups, financial burdens, unemployment) to relieve stress or forget problems.
• Iatrogenic / Irrational Drug Use: Continuous use of a prescribed narcotic for a long time (e.g., chronic pain management) leading to accidental dependence.
• Genetics and Family History: A family history of substance abuse greatly increases susceptibility to addiction.
• Availability and Accessibility: Easy access to prescription drugs (e.g., from family medicine cabinets or occupational exposure for healthcare workers) or illicit street drugs.
• Self-Medication: People with underlying mental health conditions (like ADHD, Depression, or severe anxiety) may use narcotics to self-medicate.
• Socio-economic factors: Poverty, high work pressure, illegal relationships, and weak drug enforcement laws.

• Accidents and severe cognitive impairment.
• Respiratory illness, pneumonia, and ultimately respiratory arrest.
• Cardiovascular illness and Hypovolemia/hypotension.
• Seizures, delirium, and coma.
• Opioid hyperalgesia: A paradoxical increase in pain sensitivity.
• Infectious Complications (from IV drug use): Infections at the injection site (abscesses, cellulitis), infective endocarditis, and transmission of blood-borne viruses like HIV and Hepatitis B/C.
• Severe constipation and bowel obstruction.

Intoxication can range from mild to life-threatening. Mental status effects include euphoria, sedation, decreased anxiety, a sense of tranquility, and indifference to pain. Severe intoxication leads to the classic Opioid Overdose Triad.

Other signs include: Slurred speech, hypothermia, cyanosis, needle marks/tracks, and increased sphincter tone leading to urinary retention.

Withdrawal occurs when a physically dependent person stops taking the drug. Symptoms are intensely uncomfortable but rarely fatal.

• Early Symptoms: Anxiety, agitation, craving, yawning, running nose (rhinorrhea), excessive salivation, and sweating.
• Late Symptoms: Wide (dilated) pupils (mydriasis), tachypnea, tachycardia, severe muscle aches and bone pain, tremors, lack of appetite, severe abdominal cramps, diarrhea, nausea, and vomiting.

• Immediate Triage: Patients arriving with suspected narcotic overdose are highly critical. They are often brought in unconscious by bystanders or EMS.
• A-B-C Approach:
  • Airway: Check if the airway is patent. Clear vomitus or secretions.
  • Breathing: Assess respiratory rate and depth. If the patient is apneic or taking shallow breaths (e.g., 4 breaths/min), initiate bag-valve-mask (BVM) ventilation with 100% oxygen immediately.
  • Circulation: Assess pulses and blood pressure.
• Move to Resuscitation Area: Any patient with a depressed level of consciousness and respiratory depression must be immediately moved to the Resuscitation/Emergency bay.

• Vital Signs: Continuous SpO2, cardiac monitoring, and frequent BP checks.
• Neurological Assessment: Check GCS (Glasgow Coma Scale) and examine pupils for miosis (pinpoint).
• Collateral History: Ask paramedics or bystanders about the scene (empty pill bottles, syringes, history of drug abuse).
• Screening Tools (for stable/conscious patients): Use the CAGE-AID questionnaire (Adapted to Include Drugs):
  1. Have you ever felt you ought to Cut down on your drug use?
  2. Have people Annoyed you by criticizing your drug use?
  3. Have you felt bad or Guilty about your drug use?
  4. Have you ever had an Eye-opener (used drugs first thing in the morning to steady nerves or get rid of a hangover)?
• Investigations:
  • Point-of-care capillary blood glucose (to rule out hypoglycemia causing coma).
  • Urine Toxicology screen (confirms presence of opiates).
  • Arterial Blood Gas (ABG) to check for hypoxia and hypercapnia.
  • ECG (to check for QTc prolongation or arrhythmias, especially with Methadone abuse).
  • Screening for HIV, Hepatitis B/C if IV drug use is suspected.

The primary goal is reversing respiratory depression. Secure IV access immediately.

Antidote	Mechanism & Characteristics	Dosage / Administration
Naloxone (Narcan)	A pure, short-acting competitive opioid receptor antagonist. It reverses the effects of narcotics (especially respiratory depression) in 1-5 minutes. Warning: Its half-life (30-90 mins) is much shorter than most narcotics. The patient may slip back into a coma once it wears off, requiring continuous observation or a continuous IV infusion.	0.4 mg to 2 mg IV, IM, SC, or Intranasally. Can be repeated every 2-3 minutes until respiration improves.
Naltrexone	A long-acting narcotic antagonist. It is NOT used for acute overdose. It is used for maintenance therapy to prevent relapse after a patient has been fully detoxified (opioid-free for 7-10 days).	Typically 50 mg PO daily for maintenance.
Nalmefene	Similar to naloxone but with a significantly longer half-life, reducing the need for continuous infusions.	0.5 mg to 1.5 mg IV.

Note on Antidote Administration: Administering Naloxone to a physically dependent patient will precipitate immediate and severe withdrawal symptoms. Be prepared for agitation, vomiting, and combativeness upon waking.

• ICU / High Dependency Unit (HDU): Patients requiring intubation, mechanical ventilation, or a continuous Naloxone infusion due to long-acting narcotic overdose (e.g., Methadone) must be admitted here.
• General Medical Ward / Toxicology Unit: Stable patients who are conscious and breathing adequately, but need observation for 24-48 hours to manage withdrawal and monitor for secondary complications (e.g., aspiration pneumonia).
• Psychiatric / Rehabilitation Center: Once medically cleared, patients with severe opioid use disorder should be transferred to specialized psychiatric or rehab centers for detox and long-term management.

The patient must be motivated and helped to appreciate the disadvantages of drug use. The withdrawal severity is often measured using the COWS (Clinical Opiate Withdrawal Scale). Management involves Medication-Assisted Treatment (MAT):

• Agonist Substitution Therapy: Substituting the abused drug with a controlled, long-acting opioid to taper them down slowly without euphoria.
  • Methadone: A long-acting synthetic opioid.
  • Buprenorphine: A partial opioid agonist, often combined with naloxone (Suboxone) to prevent IV abuse.
• Non-Opioid Symptomatic Control:
  • Clonidine: An alpha-2 agonist that heavily relieves autonomic withdrawal symptoms such as salivation, running nose, sweating, muscle aches, and anxiety.
  • Diazepam or Chlordiazepoxide: Benzos for severe anxiety or agitation.
  • Carbamazepine: 200-400mg BD to guard against seizures.
  • Loperamide / Antiemetics: For diarrhea and vomiting.
  • Vitamin B Complex & Multivitamins: For nutritional support.

Addiction is a chronic, relapsing disease. Medical detox is only the first step. Long-term treatment includes:

• Motivational Counseling: Show the patient they have a problem, identify root causes, and help them build problem-solving skills.
• Relapse Prevention: Observe behavioral changes, recognize craving triggers, and ensure the client cannot easily access the substance.
• Group Therapy and Counseling (CBT): Help the client manage difficult feelings, encourage assertiveness, identify relaxation techniques, and use leisure time constructively.
• Social Reintegration: Encourage support from family and friends. Encourage joining supportive groups like Narcotics Anonymous (NA).
• Vocational Rehabilitation: Train the client in skills/activities to keep them busy and earn a living.

• Legal Compliance (Lock and Key): Narcotics are strictly regulated by federal/national law. Maintain the drugs under double lock and key. The nurse must record the date, time, client's name, type, and amount of the drug used, and sign the entry in a narcotic inventory sheet.
• Wastage Protocols: If a narcotic drug must be wasted (partially used ampoule), the act must be witnessed by another qualified nurse, and the narcotic sheet must be signed by both the administering nurse and the witness. Computerized narcotic documentation systems should be utilized where available.
• Antidote Readiness: Always keep narcotic antagonists such as Naloxone readily available on the ward emergency trolley to treat respiratory depression.
• Pre-Administration Assessment:
  • Assess allergies or adverse effects from narcotics previously experienced by the client.
  • Assess for any respiratory disease (such as asthma or COPD) that might severely increase the risk of respiratory depression.
  • Assess the characteristics of pain and the effectiveness of previous pain medications.
  • Take and record baseline vital parameters (especially Respiratory Rate and SpO2) before administering the drug.
• Post-Administration Monitoring: Monitor vital signs, Level of Consciousness (L.O.C), pupillary response, bowel function (for severe constipation), urinary function (for retention), and the effectiveness of pain management.
• Alternative Therapies: Teach and apply non-invasive methods of pain management (e.g., positioning, ice/heat, distraction) in conjunction with narcotic analgesics to avoid narcotic overuse.
• Avoid Long-term Therapy: Work with physicians to taper narcotics early and avoid long-term therapy unless absolutely medically necessary (e.g., palliative care).

No.	Nursing Diagnosis	Interventions & Rationale
1	Ineffective Breathing Pattern related to CNS and respiratory center depression secondary to narcotic overdose.	Monitor RR, depth, and SpO2 continuously: Identifies need for immediate intervention. Administer 100% Oxygen and assist ventilation with BVM if RR < 8: Maintains oxygenation to prevent brain death. Administer Naloxone IV as prescribed: Competitively binds opioid receptors to rapidly reverse respiratory depression.
2	Risk for Aspiration related to depressed level of consciousness and depressed gag reflex.	Position patient in lateral recovery position: Prevents tongue from occluding airway and allows drainage of vomitus. Keep suction equipment at bedside: Ready for immediate clearing of airway if the patient vomits (highly likely after Naloxone administration).
3	Acute Pain / Discomfort related to abrupt opioid withdrawal syndrome.	Assess withdrawal severity using COWS scale: Guides medication dosing. Administer Clonidine and symptom-relief medications as ordered: Reduces autonomic hyperactivity and physical pain associated with withdrawal. Provide a quiet, dim, non-stimulating environment: Reduces sensory overload which exacerbates withdrawal anxiety.
4	Ineffective Coping related to psychological dependence and lack of problem-solving skills.	Establish a non-judgmental, therapeutic relationship: Builds trust, encouraging the patient to express feelings about drug use honestly. Assist client to identify triggers for use: Awareness is the first step in relapse prevention. Refer to substance abuse counseling and NA groups: Provides long-term community and psychological support.

• Proper Medical Use: Reassure patients that the use of narcotics to treat severe, acute pain (under strict doctor supervision) is unlikely to cause addiction. Take drugs exactly as prescribed.
• Avoid CNS Depressants: Do not drink alcohol or take over-the-counter medications (like antihistamines or sleep aids) unless approved by the health care provider, as this causes fatal respiratory depression.
• Dietary Adjustments: Increase intake of fluids and fiber in the diet to prevent severe narcotic-induced constipation.
• Safety Precautions: The drugs often cause dizziness, drowsiness, and impaired thinking. Use extreme caution when driving, operating machinery, or making important decisions.
• Reporting Symptoms: Report decreasing effectiveness (tolerance) or the appearance of adverse side effects to the physician immediately. Do not self-increase the dose.
• Overdose Awareness: Teach family members the signs of the overdose triad (coma, slow breathing, pinpoint pupils) and, where available, how to administer take-home emergency Naloxone nasal sprays.
• Coping Mechanisms: Encourage the client to develop effective coping mechanisms for stress (e.g., exercise, talking to friends) rather than turning to substance use.

An adverse drug reaction is a broad term encompassing any unwanted, uncomfortable, or dangerous effect caused by a drug. Understanding ADRs, their classifications, and underlying pharmacological mechanisms is a cornerstone of safe clinical practice and patient care.

• Definition of terms associated with Adverse Drug Reactions (ADRs).
• Classification of ADRs.
• Discussion on each type of ADR with comprehensive pharmacological examples.

It is crucial to differentiate between an event and a reaction to establish causality in pharmacovigilance.

• Adverse Event (AE) / Effect or Experience: Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment.
• Adverse Drug Event (ADE): An AE which happens in a patient taking a drug.
• Adverse: Untoward, unintended, possibly causing harm (noxious).
• Adverse Drug Reaction (ADR): Any noxious change which is suspected to be due to a drug, occurs at doses normally used in man, requires treatment or decrease in dose, or indicates caution in future use of the same drug. Therefore, an adverse drug reaction is an ADE in which a causal association is suspected or established between the drug and the event.

1. Drug Administered: The patient is given a medication.
2. New Condition/Symptom (ADE): The patient develops an untoward clinical manifestation.
3. Drug Suspected? (Yes): The clinician suspects the drug is responsible.
4. Check Literature:
   • Documented: If the reaction is documented for the product or similar class of products → Highly suggestive of ADR.
   • Not documented in literature: The physician must test via dechallenge and rechallenge.
5. Dechallenge/Rechallenge Process (for undocumented effects):
   • Drug Continued: Worsening of symptoms occurs. The clinician must ask: Are there any other possible causes? (Concomitant therapy, underlying conditions).
   • Drug Discontinued (Dechallenge): If symptoms improve, this is a Positive (+ve) Dechallenge.
   • Drug Restarted (Rechallenge): If symptoms recur upon re-administration, this is a Positive (+ve) Rechallenge, confirming the ADR.

Adverse drug reactions can be classified using several parameters to aid in diagnosis, reporting, and management.

• Acute: Occurs in < 60 minutes (e.g., Anaphylaxis).
• Sub-acute: Occurs in 1 to 24 hours (e.g., Maculopapular rash).
• Latent: Occurs in > 2 days (e.g., Drug-induced liver injury, teratogenesis).

• Minor ADRs: No therapy, antidote, or prolongation of hospitalization is required.
• Moderate ADRs: Requires a change in drug therapy, specific treatment, or prolongs hospital stay by at least 1 day.
• Severe ADRs: Potentially life-threatening, causes permanent damage, or requires intensive medical treatment.
• Lethal: Directly or indirectly contributes to the death of the patient.

The Wills and Brown classification system categorizes ADRs alphabetically from A to H, and U.

• Type A (Augmented)
• Type B (Bizarre)
• Type C (Chemical)
• Type D (Delayed)
• Type E (Exit / End of treatment)
• Type F (Familial)
• Type G (Genotoxicity)
• Type H (Hypersensitivity)
• Type U (Unclassified)

• Reactions which can be predicted from the known pharmacology of the drug.
• Dose-dependent.
• Can be alleviated by a dose reduction.

• Anticoagulants → Bleeding: Drugs like Warfarin (Vitamin K antagonist) or Heparin (activates antithrombin III) have a primary therapeutic action of preventing clot formation. An augmented effect of this known pharmacology naturally leads to spontaneous bleeding or hemorrhage if the dose is too high (e.g., high INR/aPTT).
• Beta Blockers → Bradycardia: Medications like Metoprolol or Propranolol competitively block beta-1 adrenergic receptors in the heart, preventing sympathetic (epinephrine/norepinephrine) stimulation. While intended to lower blood pressure or control arrhythmias, exaggerated blockade excessively slows the SA node, causing predictable bradycardia.
• Nitrates → Headache: Nitroglycerin is converted to nitric oxide (NO), stimulating cGMP and causing smooth muscle relaxation. While intended for coronary arteries to treat angina, it also causes profound vasodilation of the meningeal and cerebral blood vessels, predictably leading to a throbbing headache.
• Prazosin → Postural hypotension: Prazosin is an alpha-1 adrenergic antagonist. It blocks the receptors that normally maintain venous and arterial tone. When a patient stands, the inability of the blood vessels to constrict (due to alpha-1 blockade) causes blood to pool in the lower extremities, leading to a precipitous drop in blood pressure (orthostatic/postural hypotension).

• Cannot be predicted from the pharmacology of the drug.
• Not dose-dependent.
• Host-dependent factors (like genetics or immunological state) are important in predisposition.

• Penicillin → Anaphylaxis: The beta-lactam ring of penicillin can act as a hapten, binding to host proteins and triggering an unpredictable, massive IgE-mediated mast cell degranulation (Type I hypersensitivity) in susceptible individuals, leading to anaphylactic shock.
• Anticonvulsants → Hypersensitivity: Drugs like Phenytoin or Carbamazepine can cause unpredictable immune-mediated reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or DRESS syndrome. This is often linked to specific HLA genotypes (e.g., HLA-B*1502) affecting how the host metabolizes toxic arene oxide intermediates.

• Biological characteristics can be predicted from the chemical structure of the drug or its metabolite.

• Paracetamol (Acetaminophen) → Hepatotoxicity: Paracetamol is normally metabolized by glucuronidation and sulfation. However, a minor pathway via CYP450 enzymes produces a highly toxic, highly reactive intermediate metabolite called NAPQI (N-acetyl-p-benzoquinone imine). In overdose, glutathione stores are depleted, and NAPQI covalently binds to hepatic cellular proteins, causing predictable centrilobular hepatic necrosis.

• Occur after many years of treatment or post-exposure.
• Can be due to drug or metabolite accumulation.

• Chemotherapy → Secondary tumours: Alkylating agents (e.g., Cyclophosphamide) directly cross-link and damage DNA. While they kill primary cancer cells, the cumulative genetic mutations in healthy stem cells can lead to secondary malignancies, such as leukemia, emerging years later.
• Phenytoin during pregnancy → Teratogenic effects: Exposure in utero can lead to "Fetal Hydantoin Syndrome," characterized by craniofacial anomalies (cleft lip/palate), hypoplastic nails, and developmental delays, manifesting as the child grows.
• Antipsychotics → Tardive dyskinesia: Long-term use of typical antipsychotics (e.g., Haloperidol) causes chronic blockade of dopamine (D2) receptors in the nigrostriatal pathway. Over years, this leads to an unpredictable up-regulation and hypersensitivity of these receptors, resulting in delayed, involuntary, repetitive body movements.
• Analgesics → Nephropathy: Chronic, long-term use of NSAIDs inhibits vasodilatory prostaglandins in the kidneys, leading to chronic renal ischemia, papillary necrosis, and chronic interstitial nephritis ("analgesic nephropathy") over years of accumulated use.

• Occur on withdrawal, especially when a drug is stopped abruptly.

• Phenytoin withdrawal → Seizures: Abrupt cessation of an anticonvulsant removes the pharmacological suppression of neuronal firing. The central nervous system experiences "rebound excitability," which can precipitate severe withdrawal seizures or status epilepticus.
• Steroid withdrawal → Adrenocortical insufficiency: Exogenous corticosteroids (e.g., Prednisone) exert negative feedback on the Hypothalamic-Pituitary-Adrenal (HPA) axis, shutting down endogenous cortisol production. If stopped abruptly, the atrophied adrenal glands cannot produce enough cortisol to meet physiological demands, leading to a life-threatening acute adrenal crisis.

• Unwanted but often unavoidable, pharmacodynamic effects that occur at therapeutic doses.
• Predicted from the pharmacological profile of a drug.
• Known to occur in a given percentage of drug recipients.

• Atropine (preanaesthetic) → Dryness of mouth: Atropine is a muscarinic acetylcholine receptor antagonist used to reduce airway secretions during surgery. Because it systemically blocks muscarinic receptors, it unavoidably blocks M3 receptors in the salivary glands, causing a dry mouth.
• Acetazolamide (diuretic) → Acidosis: A carbonic anhydrase inhibitor that forces the renal excretion of bicarbonate to induce diuresis. The loss of the body's primary buffer (bicarbonate) naturally leads to a mild metabolic acidosis.

• Promethazine (anti-allergic) → Sedation: It is a first-generation H1 receptor antagonist intended to block peripheral histamine to stop allergies. However, it is highly lipophilic, crosses the blood-brain barrier, and blocks central H1 receptors, leading to significant sedation.
• Estrogen (Anti-ovulatory / Contraceptive) → Nausea: Estrogen acts centrally on the chemoreceptor trigger zone (CTZ) in the brainstem and can irritate the gastric lining, causing a high incidence of nausea as a side effect.

• Codeine (anti-tussive) → Constipation → Used in Traveller's diarrhea: Codeine acts on mu-opioid receptors. In the medullary cough center, it stops coughing. In the GI tract, it decreases peristalsis. While constipation is an unwanted side effect when treating a cough, this exact pharmacodynamic effect is therapeutically exploited to treat diarrhea.

Occasionally, "adverse" effects may be exploited to develop an entirely new indication for a drug.

• Minoxidil: Originally developed as a potent potassium-channel-opening vasodilator for severely hypertensive patients. An unwanted side effect was hypertrichosis (hair growth). It was subsequently developed as a topical treatment for alopecia.
• Sildenafil: Initially developed as an antianginal medication to dilate coronary arteries. Its pronounced effect on alleviating erectile dysfunction (by inhibiting PDE-5 and increasing cGMP in the corpus cavernosum) led to a new drug indication.
• Sulfonamides: Used as antibacterials, they were found to produce hypoglycemia and acidosis as side effects. This led directly to the development of Hypoglycemic Sulfonylureas (for diabetes) and the Carbonic Anhydrase inhibitor Acetazolamide (for glaucoma/diuresis).

Indirect consequences of a primary action of the drug.

• Tetracyclines → Suppression of bacterial flora → Superinfections: These broad-spectrum antibiotics kill normal, healthy gastrointestinal and vaginal flora. This secondary disruption allows opportunistic, resistant pathogens (like Candida albicans or Clostridium difficile) to overgrow, causing superinfections.
• Corticosteroids → Weaken host defence → Activation of latent tuberculosis: Steroids profoundly suppress cell-mediated immunity (T-cells and macrophages). This indirect effect allows dormant granulomas containing Mycobacterium tuberculosis to break open and reactivate.

Result of excessive pharmacological action of the drug due to over dosage or prolonged use. Overdosage may be:

• 1. Absolute: Accidental, homicidal, or suicidal ingestion of a massive dose.
• 2. Relative: Normal dose given to a patient with impaired clearance (e.g., Gentamycin in a patient with Renal failure, leading to toxic accumulation and ototoxicity/nephrotoxicity).

1. Extension of therapeutic effect:
   • Barbiturates → Coma: (Over-facilitation of GABA-A receptors depressing the entire CNS).
   • Digoxin → Complete A-V block: (Excessive vagal tone and Na/K ATPase inhibition completely stopping atrioventricular conduction).
   • Heparin → Bleeding: (Excessive anticoagulation).
2. Functional alteration:
   • Atropine → Delirium: (Excessive central anticholinergic toxicity leads to hallucinations and delirium, independent of its intended peripheral effects).
3. Drug induced tissue damage:
   • Paracetamol → Hepatic necrosis: (Via toxic NAPQI metabolite).

• Appearance of characteristic toxic effects of a drug in an individual at therapeutic doses.
• It is the converse of tolerance and indicates a very low threshold of the individual to the drug's normal actions.
• Triflupromazine (single dose) → Muscular dystonias in some individuals (acute extrapyramidal symptoms from standard D2 blockade).
• Carbamazepine (few doses) → Ataxia in some individuals (excessive sodium channel blockade in the cerebellum at low doses).
• Chloroquine (single tablet) → Vomiting and abdominal pain in some individuals.

• Genetically determined abnormal reactivity to a chemical.
• Certain bizarre drug effects due to peculiarities of an individual for which no definite genotype has been described are also included.
• The drug interacts with some unique feature of the individual, not found in the majority of subjects, and produces an uncharacteristic reaction.
• Barbiturates → Excitement and mental confusion in some individuals (paradoxical reaction).
• Quinine → Cramps, diarrhea, asthma, vascular collapse in some individuals (severe idiosyncratic reaction known as Cinchonism).
• Chloramphenicol → Aplastic anemia in rare individuals (idiosyncratic, non-dose-dependent bone marrow failure due to genetic susceptibility affecting mitochondrial protein synthesis).

Immunologically mediated reaction producing stereotype symptoms, unrelated to the pharmacodynamic profile of the drug. Generally occurs even with much smaller doses.

• Type I: Immediate, anaphylactic (IgE-mediated)
  • Penicillins → Anaphylaxis
• Type II: Cytotoxic antibody (IgG, IgM-mediated)
  • Methyldopa → Hemolytic anemia (Drug binds to RBC membrane; IgG antibodies attack and destroy the red blood cells).
• Type III: Serum sickness (IgG, IgM Antigen-antibody complex)
  • Procainamide-induced lupus (Complexes of drug and antibodies deposit in tissues and joints, causing systemic lupus erythematosus-like symptoms).
• Note: Types I, II, and III constitute Humoral immunity.
• Type IV: Delayed hypersensitivity (T cell-mediated)
  • Contact dermatitis (Topical drug exposure activates localized T-cells leading to delayed skin inflammation).
• Note: Type IV constitutes Cell-mediated immunity.

Cutaneous reaction resulting from drug-induced sensitization of the skin to UV radiation. The reactions are of two types:

• Phototoxic: Drug or its metabolite accumulates in the skin, absorbs light, and undergoes a photochemical reaction resulting in local tissue damage (sunburn-like, i.e., erythema, edema, blistering, hyperpigmentation).
  • Tetracyclines (esp. Demeclocycline), Tar products, Nalidixic acid, Fluoroquinolones, Sulfones, etc.
• Photo allergic: Drug or its metabolite induces a cell-mediated immune response which on exposure to light (longer wave length) produces a papular or eczematous contact dermatitis-like picture.
  • Sulfonamides, Sulfonylureas, Griseofulvin, Chloroquine, Chlorpromazine.

Drugs capable of altering mood and feelings are liable to repetitive use to derive euphoria, withdrawal from reality, social adjustment, etc.

• Psychological dependence: Individual believes that optimal state of well being is achieved only through the actions of the drug. (e.g., Opioids, Cocaine).
• Physical dependence: Altered physiological state produced by repeated administration of a drug which necessitates the continued presence of the drug to maintain physiological equilibrium. Discontinuation of the drug results in a characteristic withdrawal (abstinence) syndrome. (e.g., Opioids, Barbiturates, Alcohol, Benzodiazepines).

• Drug abuse: Use of a drug by self medication in a manner and amount, that deviates from the approved medical and social patterns in a given culture at a given time. Refers to any use of an illicit drug.
• Drug addiction: Compulsive drug use characterized by overwhelming involvement with the use of a drug.
• Drug habituation: Less intensive involvement with the drug, withdrawal produces only mild discomfort.
• Habituation and addiction imply different degrees of psychological dependence.

Sudden interruption of therapy with certain drugs result in adverse consequences, mostly in the form of worsening of the clinical condition for which the drug was being used.

• Corticosteroid → Adrenal insufficiency
• β-blockers → Worsening of angina, precipitation of Myocardial Infarction (MI) (Due to up-regulation of beta receptors during chronic blockade; abrupt withdrawal leaves the heart hypersensitive to endogenous catecholamines).
• Clonidine → Severe HTN, restlessness, sympathetic over activity (Alpha-2 agonist withdrawal removes central sympathetic inhibition, causing a massive rebound catecholamine release).

Capacity of a drug to cause foetal abnormalities when administered to the pregnant mother. Drugs can affect the foetus at 3 stages:

1. Fertilization and implantation (Conception to 17 days): Failure of pregnancy which often goes unnoticed (all-or-nothing effect).
2. Organogenesis (18 days to 55 days): Most vulnerable period, major structural deformities are produced.
3. Growth and development (> 56 days): Developmental and functional abnormalities can occur.

• Thalidomide → Phocomelia, multiple defects (Thalidomide acts as an angiogenesis inhibitor, preventing proper blood vessel formation required for limb bud development in the fetus).
• Anticancer drugs → Cleft palate, hydrocephalus, multiple defects (Directly disrupts DNA synthesis and rapid cell division in the developing embryo).
• ACE inhibitors → Hypoplasia of organs (lungs, kidney) (Blocks the fetal renin-angiotensin system, causing severe fetal hypotension, renal failure, and oligohydramnios, which restricts lung development).

Capacity of a drug to cause genetic defects and cancer respectively. Chemical carcinogenesis generally takes several (10-40) years to develop.

• Anticancer drugs (Direct DNA damage/alkylation).
• Radio-isotypes (Radiation-induced chromosomal breaks).
• Estrogens (Proliferative stimuli on hormone-sensitive tissues like endometrium/breast).
• Tobacco (Contains numerous chemical carcinogens like benzopyrenes).

Also called Iatrogenic (Physician induced) diseases. Functional disturbances caused by drugs which persist even after the offending drug has been withdrawn and largely eliminated.

• Salicylates (Aspirin), Corticosteroids → Peptic ulcer (Aspirin inhibits COX-1, depleting protective gastric prostaglandins. Corticosteroids decrease gastric mucosal cell renewal).
• Phenothiazines, other antipsychotics → Parkinsonism (Chronic dopamine D2 receptor blockade in the basal ganglia mimics the pathology of Parkinson's disease).
• Isoniazid → Hepatitis (Metabolized into toxic hydrazine metabolites that damage hepatocytes).
• Hydralazine → DLE (Discoid / Drug-induced Lupus Erythematosus) (Alters host proteins in slow acetylators, triggering an autoimmune antibody response against the host's own DNA).

• Adverse Drug Reactions (ADRs) are adverse events with a causal link to a drug.
• Types of Classification of ADRs:
  • Onset of event: Acute (<60 minutes), Sub-acute (1-24 hrs) and Latent (>2 days).
  • Type of reaction: Type A (Augmented), B (Bizarre), C (Chemical), D (Delayed), E (Exit), F (Familial), G (Genotoxicity), H (Hypersensitivity), U (Unclassified).
  • Severity: Minor, Moderate, Severe, Lethal ADRs.
  • Others: Side effects, Secondary effects, Toxic effects, Intolerance, Idiosyncrasy, Drug allergy, Photosensitivity, Drug Dependence, Drug Withdrawal Reactions, Teratogenicity, Mutagenicity, Carcinogenicity, Drug induced disease (Iatrogenic).

• Bhushanam T., V. (n.d.). Adverse Drug Reactions [PDF Presentation slides].
• Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2017). Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. (Used for pharmacological expansions).
• Katzung, B. G. (2017). Basic & Clinical Pharmacology (14th ed.). McGraw-Hill Education. (Used for pharmacological expansions).
• World Health Organization (WHO). (2002). Safety of Medicines: A guide to detecting and reporting adverse drug reactions. WHO Press.